September 29, 2022 We are writing to express our strong support for the Consumer Product Safety Commission (CPSC) plan to adopt a mandatory standard for frame child carriers to improve safety by including more stringent requirements and test conditions. The National Center for Health Research (NCHR) is a nonprofit think tank that conducts, analyzes, and […]
Read More »On Medical Treatments & Products
Testimony of Dr. Diana Zuckerman About PEPAXTO FDA Advisory Committee Meeting on September 22, 2022
We testified before the FDA Advisory Committee that Pepaxto should no longer be approved for multiple myeloma because new research shows that patients taking it died 5 months sooner than patients taking a different treatment.
Read More »NCHR supports mandatory safety standards for sling baby carriers
September 15, 2022: We are writing to express our views on the Consumer Product Safety Commission’s adoption of a mandatory safety standard for infant sling carriers. We enthusiastically support the plan to make the current CPSC voluntary safety standards – which address product test methods, performance requirements, labeling and instructional literature –mandatory for manufacturers in […]
Read More »Dr. Diana Zuckerman Statement to CDC Advisory Committee On Breast Cancer in Young Women
August 23, 2022: Research shows that many young women are disproportionately afraid of breast cancer and that young breast cancer survivors are more afraid of recurrence than older survivors. I encourage you to think of what we can do together to help reduce that fear so that young women don’t let their fear overwhelm them as they become aware of and educated about their risks as well as their prevention and treatment options.
Read More »NCHR Public Comment on AHRQ Draft Review on Partial Breast Irradiation and Whole Breast Irradiation for Breast Cancer
The National Center for Health Research supports AHRQ's draft review finding that partial breast irradiation (PBI) is effective for select early-stage breast cancer patients, with most outcomes comparable to whole breast irradiation (WBI) at 5-10 years. NCHR emphasizes the need for additional research on different PBI types and long-term outcomes at 15-20 years, particularly across diverse patient populations.
Read More »